Imugene (IMU.AX) Osake Kurssi
Imugene Kurssi
Liikevaihto on kasvanut 55,4 % vuodessa viimeisten 18 vuoden aikana 4,40 M AUD:een. Imugenen nettomarginaali on nyt −1 569,8 %, laskenut −255,2 %:sta muutama vuosi sitten.
Imugene osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Imugene liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Imugene -osakkeesta
Imugene Ltd is a biotechnology company specializing in the development and commercialization of innovative immunotherapies for the treatment of various cancers. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to create targeted and personalized immunotherapies that activate the body's own immune system to fight cancer. Imugene aims to improve patient outcomes and address the unmet medical needs in oncology by advancing their immunotherapy pipeline. With a focus on developing novel treatments and strategic partnerships, Imugene is dedicated to making a significant impact in the field of cancer immunotherapies.
Imugene Ltd is primarily active in the biotechnology industry.
The main competitors of Imugene Ltd in the market include major biopharmaceutical companies such as Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb Company, and Pfizer Inc. These companies also specialize in developing innovative treatments and therapies for various diseases and disorders.
Imugene Ltd is a biopharmaceutical company dedicated to developing innovative immunotherapies to treat cancer. Founded in 1983, Imugene has a rich history in the field of oncology research and drug development. The company focuses on creating targeted immunotherapies that harness the power of the immune system to fight cancer cells. Imugene is committed to addressing unmet medical needs and improving patient outcomes. With a strong team of experienced scientists and a robust pipeline of promising drug candidates, Imugene aims to revolutionize cancer treatment and provide hope to patients worldwide. Imugene Ltd continues to strive towards its mission of developing much-needed advancements in the oncology field.
Imugene Ltd has achieved several significant milestones. The company successfully completed a Phase 1b study for its HER-Vaxx cancer immunotherapy in gastric cancer patients. Imugene also received approval from the US FDA to initiate its Phase 2 study for HER-Vaxx in gastric cancer. Additionally, Imugene has entered collaborations with renowned academic institutions, including City of Hope, to conduct preclinical and clinical trials for various cancer treatments. The company has made considerable progress in advancing its innovative immunotherapy pipeline, which shows great potential in the field of oncology. Imugene Ltd continues to strive for excellence and breakthroughs in cancer treatments.
Imugene Ltd is primarily present in Australia, United States, and Europe.
Imugene Ltd represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company aims to revolutionize cancer treatment through its cutting-edge immunotherapy technologies. Imugene prioritizes scientific expertise and fosters strategic partnerships to advance its pipeline of novel and targeted therapies. The company's commitment to improving treatment outcomes for patients is evidenced by its emphasis on clinical development, rigorous research, and commercialization of innovative products. Imugene's inclusive approach promotes open communication and collaboration among researchers, clinicians, and industry experts, reinforcing its dedication to making a significant impact in the fight against cancer.
5 analyytikkoa arvioi tällä hetkellä Imugene-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla Imugene-osake noteerataan hintaan 0,02 EUR (0,04 AUD).
Imugene-osake (IMU.AX) on listattuna 2 pörssissä, muun muassa: ASX (IMU.AX).
Imugene Ltd is an Australian biopharmaceutical company that focuses on researching, developing, and marketing innovative therapeutic solutions for the treatment of cancer and infectious diseases. The company uses a unique technology platform to responsibly develop immuno-oncology products. Imugene is headquartered in Sydney, Australia, and has additional offices in the USA and Europe. The four main business areas of Imugene are: 1) Immuno-Oncology Products, 2) Immunomodulating Solutions in Cancer, 3) Infectious Diseases, and 4) Partner Programs. Imugene aims to expand its portfolio of immunotherapeutics through new product development and collaborations. It strives to revolutionize the treatment of cancer and infectious diseases with its unique technology platform and comprehensive portfolio of immunotherapeutics. Imugene is well-positioned to become a leading player in the biopharmaceutical industry with its presence in Australia, the USA, and Europe.
Liikevaihtoa ei voida laskea Imugene:lle tällä hetkellä.
voitto Imugene on −105,34 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Imugene:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,12. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Imugene-osakkeen arvostusta.
P/S-suhdetta ei voida laskea Imugene:lle tällä hetkellä.
Imugene:n Eulpool-laatuscore on 4/10.
Imugene:n ISIN on AU000000IMU9. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Imugene:n WKN on 891460. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Imugene:n ticker on IMU.AX. Tämä pörssinoteeraus käytetään Imugene-osakkeiden kauppaan pörssissä.
Imugene osake
Imugene vertaisryhmä
Imugene Ticker
Imugene FIGI
Kaikki tunnusluvut ja syvällinen analyysi Imugene:sta
Meidän osakeanalyysimme Imugene-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Imugene:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: